SOX2 and prostate cancer: SOX2 was selected over OCT4 due to its higher detectability in plasma, independent oncogenic role in epithelial tumors, and documented expression in colorectal, breast, and prostate cancers, making it a more relevant candidate for plasma-based screening in these malignancies.